
Eli Lilly to Acquire AtaiBeckley for up to $3.8 Billion, Entering Psychedelic Drug Market
The pharmaceutical giant will pay $2.8 billion upfront to gain access to AtaiBeckley's late-stage nasal spray for treatment-resistant depression, marking a significant move into psychedelic-based therapies.







